BLISS-LN (Belimumab International Lupus Nephritis Study)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab Plus Standard of Care as Induction and Maintenance Therapy for Active Lupus Nephritis



Key eligibility criteria:

- Adults, autoantibody-positive systemic lupus erythematosus
- Active, biopsy proven nephritis, biopsy within 6 months of baseline: Class III/IV/V
- Clinically active renal disease at screening
  - Urinary protein/creatinine ratio of ≥1.0 and active urinary sediment **OR**
  - Confirmatory biopsy within 3 months of baseline **OR**
  - Proteinuria ≥3.5 g/day
- Requiring induction therapy with high-dose corticosteroids AND either intravenous cyclophosphamide (CYC) or mycophenolate mofetil (MMF)
- Not previously failed induction with both CYC and MMF
- Not received induction therapy within 6 months prior to screening

Study enrollment is ongoing

For information about participating as a clinical site or referring a potential patient, please contact Zoë Marrs: zoe.x.marrs@gsk.com
US GSK Clinical Trials Call Center: 877 379 3718 EU GSK Clinical Trials Call Center: +44 (0) 20 8990 446 GSKClinicalSupportHD@GSK.com
ClinicalTrials.gov identifier: NCT01639339 http://clinicaltrials.gov/ct2/show/NCT01639339